Vyndaqel Interactions
There are 33 drugs known to interact with Vyndaqel (tafamidis), along with 2 disease interactions. Of the total drug interactions, 1 is major, 31 are moderate, and 1 is minor.
- View all 33 medications that may interact with Vyndaqel
- View Vyndaqel disease interactions (2)
Most frequently checked interactions
View interaction reports for Vyndaqel (tafamidis) and the medicines listed below.
- Afinitor Disperz (everolimus)
- amiodarone
- atorvastatin
- Bactrim DS (sulfamethoxazole / trimethoprim)
- Biktarvy (bictegravir / emtricitabine / tenofovir alafenamide)
- bupropion
- Copaxone (glatiramer)
- Cymbalta (duloxetine)
- Diacomit (stiripentol)
- Dyanavel XR (amphetamine)
- Eliquis (apixaban)
- Eloctate (antihemophilic factor)
- Emgality (galcanezumab)
- enalapril
- Entresto (sacubitril / valsartan)
- eplerenone
- finasteride
- gabapentin
- Jardiance (empagliflozin)
- levothyroxine
- Luxturna (voretigene neparvovec ophthalmic)
- Metoprolol Tartrate (metoprolol)
- Ocrevus (ocrelizumab)
- prednisone
- Savella (milnacipran)
- tamsulosin
- torsemide
- Trikafta (elexacaftor / ivacaftor / tezacaftor)
- Vitamin B12 (cyanocobalamin)
- Vitamin D3 (cholecalciferol)
Vyndaqel disease interactions
There are 2 disease interactions with Vyndaqel (tafamidis) which include:
Report options
QR code containing a link to this page
More about Vyndaqel (tafamidis)
- Vyndaqel consumer information
- Compare alternatives
- Pricing & coupons
- Reviews (1)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: transthyretin stabilizers
- En español
Related treatment guides
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
